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WE DANCE ROUND IN A RING AND SUPPOSE, 
BUT THE SECRET SITS IN THE MIDDLE AND KNOWS. 
ROBERTFROST 
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    Adhesion molecules are key topobiological 
components in almost any kind of cell-cell and cell- 
matrix interaction in both human physiology and 
pathology. Heterogeneous processes as platelet ad- 
hesion to subendothelial matrix components or leu- 
kocyte extravasation at sites of tissue damage are at 
least in part mediated by adhesion molecules and 
their corresponding receptors (counterreceptors). 
Using a multitude of modem analytical and prepara- 
tive approaches ranging from "simple" immunohis- 
tochemistry to cloning and gene transfer, in vitro 
studies provided detailed data on a variety of adhe- 
sion molecules and their receptors (reviewed in 1). 
However, compared to the speedy accumulation of 
basic knowledge the evaluation of the diagnostic 
usefulness of adhesion molecules is still in its in- 
fancy. 
Adhesion molecules can be divided into several 
families including integrins, cadherins, selectins, 
immunoglobulin superfamily and others. Every fam- 
ily consists of a growing number of individual mol- 
ecules which share some common characteristics. 
What criteria have to be make adhesion molecules 
reliable diagnostic parameters? First, soluble forms 
should exist to ensure measurement in blood or other 
body fluids. If such forms exist analytical proce- 
dures for their estimation have to be developed and 
carefully evaluated for the intended use. If this can 
be achieved, numerous additional questions will 
arise including reference values, specificity, sensi- 
tivity and predicative power for a given disease or its 
complication etc. Finally, the cost-benefit ratio will 
be considered due to worldwide limited financial 
resources for health-care institutions 
It is not surprising that disorders associated with the 
highest morbidity and mortality, including cardio- 
vascular diseases, diabetes and cancer, were the 
candidates for diagnostic improvement using inves- 
tigation of various adhesion molecules (reviewed in 
2). Furthermore, in these diseases adhesion mol- 
ecules may play a pathogenic role, e.g. monocyte 
adherence to vascular andothelium in early 
atherogenesis or attachment of tumor cells to from 
metastasis. 
As it is unrealistic to review available data on every 
adhesion molecule, we will restrict our efforts to the 
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proposed diagnostic usefulness of soluble intercel- 
lular adhesion molecule-1 (sICAM-1). ICAM-1 
(CD54) belongs to the immunoglobulin superfamily 
of adhesins and binds to the leukocyte integrin (32 
(CDlla/CD18). A circulating, soluble from of 
ICAM-1 (sICAM-1) has been demonstrated using 
Western Blotting (3) and an enzyme immunoassay 
was established (4). Currently, at least three enzyme 
immunoassays for the determination of sICAM-1 
are commercially available. However, due to inher- 
ent features of enzyme immunoassay technology 
(antibody specificity, calibration materials etc) these 
assays measure different concentration of sICAM- 
1 in healthy subjects as well as in various diseases. 
Therefore, results obtained by using different assays 
are only partly comparable. Authorities responsible 
for laboratory standardization are requested to coor- 
dinate efforts to standardize these assays. 
Elevated serum levels of sICAM-1 have been re- 
ported in a variety of diseases including inflamma- 
tory, immune and infectious disorders, atheroscle- 
rosis, diabetes and others(2). 
A number of studies have described increased 
sICAM-1 in cancer of different origin (2,5,6) in- 
cluding melanoma (7), gastrointestinal (8-10), 
urological (6) and hematological (6,11) malignan- 
cies. Each of these studies is essentially preliminary 
and longitudinal data is not available. Furthermore, 
convincing evidence for a good correlation to tumor 
staging and grading has not yet been communicated. 
An intriguing question concerns the cellular source 
of raised sICAM-1 in cancer patients. It has been 
proposed that sICAM-1 is shed from the tumor cell 
surface but there is limited evidence to support this 
idea (8). Alternatively, elevated sICAM-1 could be 
derived from endothelial cells and immune cells 
thus reflecting general cell activation within the 
host's defence system. Similar mechanisms are 
believed to contribute to increased sICAM-1 in type 
1 diabetes mellitus due to its autoimmune pathogen- 
esis (12). 
Data from cell culture studies suggest that various 
cytokines (IL-lp, IL-6, TNFa, interferon etc) may 
be involved in the regulation of adhesion molecules 
expression (8,10). Therefore, it can not be excluded 
that sIC AM-1 reflects cytokine-mediated upregu- 
lation and/or release of this particular adhesion 
molecule from the cell surface. As IL-6 is of central 
importance in the onset of an acute phase reaction 
we attempted to correlate sICAM-1 with the pres- 
ence of an ongoing acute phase response in colorectal 
cancer patients. Although no correction could be 
demonstrated, patients with present acute phase 
response revealed significantly higher sICAM-1 
that the acute phase-negative subgroup (Reinhardt 
et al 1994, submitted). Additional studies into the 
specificity of sICAM-1 for a given tumor and its 
progression are urgently needed. 
Expression of cell-bound ICAM-1 and shedding 
from the cell surface are apparently processes with 
different underlying regulation with consequences 
for tumor immunology and immunotherapy. Non- 
MHC-restricted cytotoxicity of tumor-infiltrating 
lymphocytes directed against tumor cells is at least 
in part meditated by tumor cell-bound ICAM-1. 
Shedding of surface ICAM-1 from melanoma cells 
inhibits the cytotoxic lymphocyte response prob- 
ably due to the inability of tumor antigen recognition 
by sIC AM-1-occupied lymphocyte ligands (13). 
This mechanism is considered important for the 
tumor cells escape from host's immune response 
resulting in rapid tumor progression and spread. 
Interestingly, recent data indicate that cytokine- 
mediated upregulation of tumor cell-bound ICAM- 
1 is not always accompanied by increased shedding 
(14). This discrepancy might be a central point for 
the effectiveness of immunotherapy in cancer. Aug- 
mentation of tumor cell-bound ICAM-1 without 
concomitanfly enhanced shedding probably increases 
the lymphocyte-mediated cytotoxicity against the 
tumor. Conversely, if both processes are upregulated, 
the net effect could be expected to be unchanged 
thus making immunostimulatory therapy an ineffec- 
tive approach in these patients. It may be that data on 
systemic sICAM-1 and basal and cytokine-stimu- 
lated expression and shedding of ICAM-1 from 
individual tumor cells will be included in the ap- 
proach to individualise tumor immunotherapy. 
Although current results on ICAM-1 might cause 
controversy and sometimes confusion, the data and 
ideas outlined so far may contribute to the conver-   
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sion of investigation of ICAM-1 in clinical onco- 
logy from an expensive toy to a reliable parameter 
for the benefit of our tumor patients. 
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